{"id":3565,"date":"2024-11-06T07:48:00","date_gmt":"2024-11-06T07:48:00","guid":{"rendered":"http:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/"},"modified":"2024-11-06T07:48:00","modified_gmt":"2024-11-06T07:48:00","slug":"%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/","title":{"rendered":"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01"},"content":{"rendered":"

\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde<\/span>2024\u5e7411\u67086\u65e5<\/span> \/\u7f8e\u901a\u793e\/ —\u00a0\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u70b9\u54c1\u79cdAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u9009\u7b2c66\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u662f\u8be5\u54c1\u79cd\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u7b2c3\u5e74\u5165\u9009ASH\u5e74\u4f1a\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u4e2a\u54c1\u79cd\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9879\u4e34\u5e8a\u548c\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5e76\u83b7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u3002<\/p>\n

\n

\n <\/a><\/p>\n

\n <\/p>\n<\/div>\n

APG-2575\uff08Lisaftoclax\uff09\u662f\u4e9a\u76db\u533b\u836f\u81ea\u4e3b\u7814\u53d1\u7684\u3001\u5177\u5168\u7403best-in-class\u6f5c\u529b\u7684\u65b0\u578b\u53e3\u670dBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\uff0c\u5728\u591a\u79cd\u8840\u6db2\u80bf\u7624\u548c\u5b9e\u4f53\u7624\u6cbb\u7597\u9886\u57df\u5177\u5907\u5e7f\u9614\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u4e9a\u76db\u533b\u836f\u5c06\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u4e0a\uff0c\u53e3\u5934\u62a5\u544a\u8be5\u54c1\u79cd\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\uff08R\/R\uff09\u591a\u53d1\u6027\u9aa8\u9ad3\u7624(MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6b64\u5916\uff0c\u5176\u8054\u5408\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6700\u65b0\u6570\u636e\u4e5f\u5c06\u4ee5\u58c1\u62a5\u5c55\u793a\u5f62\u5f0f\u516c\u5e03\u3002<\/p>\n

\u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c66\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e\u5f53\u5730\u65f6\u95f42024\u5e7412\u67087\u65e5\u81f310\u65e5\u95f4\u5728\u7f8e\u56fd\u5723\u5730\u4e9a\u54e5\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”APG-2575\uff08Lisaftoclax\uff09\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\uff0c\u76ee\u524d\u6b63\u5728\u5f00\u5c55\u56db\u9879\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u3002\u8be5\u54c1\u79cd\u7684\u591a\u4e2a\u4e34\u5e8a\u8fdb\u5c55\u518d\u6b21\u5165\u9009ASH\u5e74\u4f1a\u62a5\u544a\uff0c\u8fdb\u4e00\u6b65\u4f53\u73b0APG-2575\uff08Lisaftoclax\uff09\u8fd9\u4e00\u5168\u7403Best-in-class\u6f5c\u529b\u54c1\u79cd\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u5f3a\u52b2\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u4e2a\u91cd\u70b9\u54c1\u79cd\u6709\u591a\u9879\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5145\u5206\u663e\u73b0\u4e86\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u548c\u5f00\u53d1\u5b9e\u529b\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u7684\u8be6\u5b9e\u6570\u636e\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002”<\/p>\n

ASH 2024\u4e9a\u76db\u533b\u836f\u4ea7\u54c1\u76f8\u5173\u7814\u7a76\u4e00\u89c8\uff1a<\/p>\n

\n

\u5c55\u793a\u5f62\u5f0f<\/span><\/p>\n

\u54c1\u79cd<\/span><\/p>\n

\u6458\u8981\u6807\u9898<\/span><\/p>\n

\u7f16\u53f7<\/span><\/p>\n

\u53e3\u5934\u62a5\u544a<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Olverembatinib as Second-Line (2L) Therapy in Patients
(pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-
CML)<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3
\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597<\/span><\/p>\n

480<\/span><\/p>\n

APG-2575<\/span><\/p>\n

\uff08Lisaftoclax\uff09<\/span><\/p>\n

Lisaftoclax (APG-2575) Combined with Novel Therapeutic
Regimens in Patients (pts) with Relapsed or Refractory
Multiple Myeloma (R\/R MM) or Immunoglobulin Light-
Chain (AL) Amyloidosis<\/span><\/p>\n

Lisaftoclax\uff08APG-2575\uff09\u8054\u5408\u65b0\u578b\u6cbb\u7597\u65b9\u6848\u7528\u4e8e\u590d\u53d1\/\u96be
\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe
\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\uff08pts\uff09<\/span><\/p>\n

1022<\/span><\/p>\n

\u58c1\u62a5\u5c55\u793a<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Olverembatinib (HQP1351) Overcomes
Resistance\/Intolerance to Asciminib and Ponatinib in
Patients (pts) with Heavily Pretreated Chronic-Phase
Chronic Myeloid Leukemia (CP CML): A 1.5-Year Follow-up
Update with Comprehensive Exposure-Response (E-R)
Analyses<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u7ecf\u6df1\u5ea6\u6cbb\u7597\u7684\u6162\u6027\u671f\u6162
\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP CML\uff09\u60a3\u8005\u5bf9Asciminib\u548c
Ponatinib\u7684\u8010\u836f\/\u4e0d\u8010\u53d7\uff1a\u6765\u81ea1.5\u5e74\u968f\u8bbf\u7684\u6700\u65b0\u6570\u636e\u53ca
\u7efc\u5408\u66b4\u9732-\u53cd\u5e94\uff08E-R\uff09\u5206\u6790<\/span><\/p>\n

3151<\/span><\/p>\n

APG-2575<\/span><\/p>\n

\uff08Lisaftoclax\uff09<\/span><\/p>\n

Lisaftoclax (APG-2575) Demonstrates Activity and Safety
When Given with Accelerated Ramp-up and then Combined
with Acalabrutinib or Rituximab in Patients (pts) with
Chronic Lymphocytic Leukemia\/Small Lymphocytic
Lymphoma (CLL\/SLL), Including Those with Prior Exposure
to Venetoclax<\/span><\/p>\n

Lisaftoclax\uff08APG-2575\uff09\u5728\u5feb\u901f\u5242\u91cf\u9012\u589e\u7ed9\u836f\u540e\u4e0e\u963f\u53ef\u66ff
\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u5728\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb
\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u80bf\u7624\u6d3b
\u6027\uff0c\u5305\u62ec\u65e2\u5f80\u63a5\u53d7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005<\/span><\/p>\n

4614<\/span><\/p>\n

APG-2575<\/span><\/p>\n

\uff08Lisaftoclax\uff09<\/span><\/p>\n

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in
Combination with Azacitidine in Treatment of Patients with
Myelodysplastic Syndrome (MDS)<\/span><\/p>\n

\u65b0\u578bBcl-2\u6291\u5236\u5242Lisaftoclax\uff08APG-2575\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09<\/span><\/p>\n

3202<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

+<\/span><\/p>\n

APG-2575<\/span><\/p>\n

Safety and Efficacy of Olverembatinib (HQP1351) Combined
with Lisaftoclax (APG-2575) in Children and Adolescents
with Relapsed\/Refractory Philadelphia Chromosome\u2013
Positive Acute Lymphoblastic Leukemia (R\/R Ph+ ALL): First
Report from a Phase 1 Study<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408Lisaftoclax\uff08APG-2575\uff09
\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\u6027\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5
\uff08R\/R Ph+ ALL\uff09\u513f\u7ae5\u53ca\u9752\u5c11\u5e74\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u7597\u6027\uff1a\u4e00
\u9879I\u671f\u4e34\u5e8a\u7814\u7a76\u7684\u9996\u6b21\u62a5\u544a\u3002<\/span><\/p>\n

1443<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

A Phase 2 Study of Olverembatinib for the Treatment of
Myeloid\/Lymphoid Neoplasms with FGFR1
Rearrangement<\/span><\/p>\n

\u4e00\u9879\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u643a\u5e26FGFR1\u57fa\u56e0\u91cd\u6392\u7684\u9ad3\u7ec6
\u80de\/\u6dcb\u5df4\u7ec6\u80de\u80bf\u7624\u7684II\u671f\u4e34\u5e8a\u7814\u7a76<\/span><\/p>\n

1781<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Olverembatinib 30 Mg Versus 40 Mg Every Other Day
(QOD) in Patients with Tyrosine Kinase Inhibitor (TKI)
Resistant or Intolerant Chronic-Phase Chronic Myeloid
Leukemia (CML-CP): A Multi-Center Propensity Score-
Matched Analysis<\/span><\/p>\n

\u9694\u5929\u4e00\u6b21\uff08QOD\uff0930mg\u8f83QOD 40mg\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb
\u7597\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u8010\u836f\u6216\u4e0d\u8010\u53d7\u7684\u6162\u6027\u671f
\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML-CP\uff09\u60a3\u8005\uff1a\u4e00\u9879\u591a\u4e2d\u5fc3\u503e\u5411
\u5f97\u5206\u5339\u914d\u5206\u6790<\/span><\/p>\n

4529<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Combination of Olverembatinib and VP Regimen for
Newly Diagnosed Adult Philadelphia Chromosome-
Positive Acute Lymphoblastic Leukemia<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\u8054\u5408VP\u65b9\u6848\u6cbb\u7597\u65b0\u8bca\u65ad\u7684\u8d39\u57ce\u67d3\u8272\u4f53\u9633
\u6027\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\u6210\u4eba\u60a3\u8005<\/span><\/p>\n

1449<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Olverembatinib-Therapy in Patients with Accelerated-
Phase Chronic Myeloid Leukaemia: A Multi-Centre
Retrospective Study from China<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9879\u5728\u4e2d
\u56fd\u5f00\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u987e\u6027\u7814\u7a76<\/span><\/p>\n

1767<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n

Olverembatinib-Based Therapy in Patients with
Philadelphia Chromosome-Positive Acute Leukemia: A
Multi-Centre Retrospective Study from China<\/span><\/p>\n

\u57fa\u4e8e\u5965\u96f7\u5df4\u66ff\u5c3c\u7597\u6cd5\u6cbb\u7597\u8d39\u57ce\u67d3\u8272\u4f53\u9633\u6027\u6025\u6027\u767d\u8840
\u75c5\uff1a\u4e00\u9879\u5728\u4e2d\u56fd\u5f00\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u987e\u6027\u7814\u7a76<\/span><\/p>\n

4528<\/span><\/p>\n

APG-2575<\/span><\/p>\n

+<\/span><\/p>\n

APG-2449<\/span><\/p>\n

APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor,
Exhibits Antileukemic Activity and Enhances Lisaftoclax
(APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia
(AML)<\/span><\/p>\n

\u65b0\u578b\u5c40\u7076\u6027\u9ecf\u9644\u6fc0\u9176\uff08FAK\uff09\u6291\u5236\u5242APG-2449\u5728\u6025\u6027\u9ad3
\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e2d\u663e\u793a\u4e86\u6297\u767d\u8840\u75c5\u6d3b\u6027\u5e76\u5f3a\u5316\u4e86\u7531
Lisaftoclax\uff08APG-2575\uff09\u8bf1\u5bfc\u7684\u7ec6\u80de\u51cb\u4ea1<\/span><\/p>\n

4150<\/span><\/p>\n

APG-5918<\/span><\/p>\n

Embryonic Ectoderm Development (EED) Inhibitor APG-
5918 Demonstrates Robust Antitumor Activity in Preclinical
Models of T-Cell Lymphomas (TCLs)<\/span><\/p>\n

\u80da\u80ce\u5916\u80da\u5c42\u53d1\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5242APG-5918\u5728T\u7ec6\u80de
\u6dcb\u5df4\u7624\uff08TCL\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u663e\u793a\u4e86\u5f3a\u6548\u7684\u6297\u80bf\u7624\u6d3b\u6027<\/span><\/p>\n

1415<\/span><\/p>\n

\u5728\u7ebf\u53d1\u5e03<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

+<\/span><\/p>\n

APG-2575<\/span><\/p>\n

Olverembatinib (HQP1351) in Combination with Lisaftoclax
Overcomes Venetoclax Resistance in Preclinical Model of
Acute Myeloid Leukemia (AML)<\/span><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u8054\u5408Lisaftoclax\uff08APG-2575\uff09
\u53ef\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d
Venetoclax\u8010\u836f<\/span><\/p>\n

5777<\/span><\/p>\n<\/div>\n

APG-2575\uff08Lisaftoclax\uff09\u5165\u90092024 ASH\u5e74\u4f1a\u7684\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u8010\u7acb\u514b\u00ae\u5165\u9009ASH\u5e74\u4f1a\u7684\u6458\u8981\u8be6\u7ec6\u4fe1\u606f\u53c2\u89c1\u540c\u671f\u53d1\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u95fb\u7a3f\uff09<\/p>\n

\u53e3\u5934\u62a5\u544a<\/p>\n

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R\/R MM) or Immunoglobulin Light- Chain (AL) Amyloidosis
Lisaftoclax\uff08APG-2575\uff09\u8054\u5408\u65b0\u578b\u6cbb\u7597\u65b9\u6848\u7528\u4e8e\u590d\u53d1\/\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\uff08pts\uff09<\/p>\n

\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u5934\u62a5\u544a<\/p>\n

\u6458\u8981\u7f16\u53f7\uff1a1022<\/p>\n

\u5206\u4f1a\u573a\uff1a654. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u836f\u7269\u7597\u6cd5\uff1a\u672a\u6765\u5c55\u671b\uff1a\u7528\u4e8e\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u65b0\u836f\u548c\u8054\u5408\u7597\u6cd5<\/p>\n

\u62a5\u544a\u65f6\u95f4\uff1a<\/p>\n

2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0b\u534816:45\uff08\u7f8e\u56fd\u897f\u90e8\u65f6\u95f4\uff09
2024\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u4e8c\uff0c\u4e0a\u53488:45\uff08\u5317\u4eac\u65f6\u95f4\uff09<\/p>\n

\u7b2c\u4e00\u4f5c\u8005\uff1a\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u00a0Sikander Ailawadhi\u6559\u6388<\/p>\n

\u6838\u5fc3\u8981\u70b9\uff1a<\/p>\n

\u7814\u7a76\u80cc\u666f\uff1a<\/p>\n

MM\u7684\u7279\u5f81\u662f\u5f02\u5e38\u6d46\u7ec6\u80de\u514b\u9686\u589e\u6b96\uff0c\u5bfc\u81f4\u7834\u574f\u6027\u9aa8\u75c5\u53d8\u3001\u80be\u635f\u4f24\u3001\u8d2b\u8840\u548c\u9ad8\u9499\u8840\u75c7\u3002MM\u7684\u6cbb\u7597\u65b9\u6cd5\u5305\u62ec\u4f7f\u7528\u514d\u75ab\u8c03\u8282\u5242\u3001\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\u548c\u6297CD38\u5355\u514b\u9686\u6297\u4f53\uff0c\u4ee5\u8fbe\u5230\u75be\u75c5\u7f13\u89e3\u7684\u76ee\u7684\u3002AL\u6dc0\u7c89\u6837\u53d8\u6027\u662f\u4e00\u79cd\u7ec6\u80de\u5916\u9519\u8bef\u6298\u53e0\u86cb\u767d\u5f02\u5e38\u6c89\u79ef\u4e8e\u5404\u5668\u5b98\u5e76\u9020\u6210\u635f\u5bb3\u7684\u75be\u75c5\uff0c\u4e3b\u8981\u6cbb\u7597\u7b56\u7565\u662f\u63a8\u8fdf\u5668\u5b98\u529f\u80fd\u969c\u788d\u7684\u65f6\u95f4\u6216\u9006\u8f6c\u5668\u5b98\u529f\u80fd\u969c\u788d\u3002\u7136\u800c\uff0c\u8bb8\u591a\u60a3\u8005\u5728\u63a5\u53d7\u6807\u51c6\u7684\u4e09\u8054\u6216\u56db\u8054\u7597\u6cd5\u540e\u4f1a\u51fa\u73b0\u590d\u53d1\uff0c\u8fd9\u5c31\u9700\u8981\u91c7\u7528\u5177\u6709\u65b0\u4f5c\u7528\u673a\u5236\u7684\u5176\u4ed6\u7597\u6cd5\u3002APG-2575\uff08Lisaftoclax\uff09\u662f\u4e00\u79cd\u65b0\u578bBcl-2\u6291\u5236\u5242\uff0c\u5728\u524d\u671f\u7814\u7a76\u4e2d\u663e\u793a\u51fa\u5f88\u5f3a\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002\u5728\u6b64\uff0c\u6211\u4eec\u62a5\u544a\u4e86APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u65b0\u578b\u6cbb\u7597\u65b9\u6848\u5728R\/R MM\u6216R\/R AL\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u3002<\/p>\n

\u7814\u7a76\u4ecb\u7ecd\uff1a\u8fd9\u662f\u4e00\u9879\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027I\/II\u671f\u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n

\u5165\u7ec4\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n

\u7b26\u5408\u6761\u4ef6\u7684\u60a3\u8005\u9700 ECOG\u8bc4\u5206 \u2264 2\uff0c\u65e2\u5f80\u63a5\u53d7\u8fc7\u2265 1\u79cd\u6cbb\u7597\uff0c\u4e14\u5668\u5b98\u529f\u80fd\u6b63\u5e38\u3002R\/R AL\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u5df2\u786e\u8bca\u6709\u75c7\u72b6\u7684\u5668\u5b98\u53d7\u7d2f\u3002APG-2575\uff08Lisaftoclax\uff09\u6bcf\u65e5\u53e3\u670d\uff0c\u4ee528\u5929\u4e3a\u5468\u671f\u91cd\u590d\u7ed9\u836f\u3002\u6cca\u9a6c\u5ea6\u80fa\u3001\u8fbe\u96f7\u59a5\u5c24\u5355\u6297\u548c\u6765\u90a3\u5ea6\u80fa\u6309\u8bf4\u660e\u4e66\u7528\u6cd5\u7ed9\u836f\u3002\u5730\u585e\u7c73\u677e 40 mg\uff0820 mg\uff0c\u5e74\u9f84>75\u5c81\uff09\u572828\u5929\u5468\u671f\u7684\u7b2c1\u30018\u300115\u548c22\u5929\u7ed9\u836f\u3002\u8fd9\u9879\u7814\u7a76\u8bc4\u4f30\u4e86APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u6cca\u9a6c\u5ea6\u80fa\u548c\u5730\u585e\u7c73\u677e\u6cbb\u7597R\/R MM\u60a3\u8005\uff08Pd\uff1b\u6cbb\u7597\u7ec4A\uff09\uff1b\u8054\u5408\u8fbe\u96f7\u59a5\u5c24\u5355\u6297\u3001\u6765\u90a3\u5ea6\u80fa\u548c\u5730\u585e\u7c73\u677e\u6cbb\u7597R\/R MM\u60a3\u8005\uff08DRd\uff1b\u6cbb\u7597\u7ec4B\uff09\uff1b\u8054\u5408Pd\u65b9\u6848\u6cbb\u7597R\/R AL\u6dc0\u7c89\u6837\u53d8\u6027\uff08\u6cbb\u7597\u7ec4C\uff09\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\u622a\u81f32024\u5e745\u670829\u65e5\uff0c\u5171\u670952\u4f8b\u60a3\u8005\u5165\u7ec4\uff0c\u5176\u4e2d\u5305\u62ec42\u4f8bR\/R MM\u60a3\u8005\u548c10\u4f8bAL\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u3002\u6240\u6709\u60a3\u8005\u7684\u5e74\u9f84\u4e2d\u4f4d\u6570\uff08\u8303\u56f4\uff09\u4e3a 69.5\uff0824-88\uff09\u5c81\uff0c\u5176\u4e2d 63.5%\u4e3a\u7537\u6027\uff0c63.5%\u7684\u60a3\u8005\u5e74\u9f84\u2265 65 \u5c81\u3002\u5165\u9009\u60a3\u8005\u65e2\u5f80\u5747\u63a5\u53d7\u8fc7\u6df1\u5ea6\u6cbb\u7597\uff0c\u65e2\u5f80\u6cbb\u7597\u7ebf\u6570\u7684\u4e2d\u4f4d\u6570\uff08\u8303\u56f4\uff09\u4e3a3\uff081-19\uff09\u7ebf\u3002\u5728A\u7ec4\uff08n=35\uff09\u4e2d\uff0cAPG-2575\uff08Lisaftoclax\uff09\u6309\u6307\u5b9a\u5242\u91cf\u53e3\u670d\u7ed9\u836f\uff1a400mg\uff083\u4f8b\uff09\u3001600mg\uff084\u4f8b\uff09\u3001800mg\uff0815\u4f8b\uff09\u30011,000mg\uff087\u4f8b\uff09\u548c1,200mg\uff086\u4f8b\uff09\u3002\u5728B\u7ec4\uff08n=7\uff09\u4e2d\uff0c\u6240\u6709\u60a3\u8005\u90fd\u63a5\u53d7\u4e86600mg APG-2575\uff08Lisaftoclax\uff09\u7684\u6cbb\u7597\u3002\u5728 C \u7ec4\uff08n=10\uff09\u4e2d\uff0c\u7ed9\u836f\u5242\u91cf\u5206\u522b\u4e3a400 mg\uff081\u4f8b\uff09\u3001600 mg\uff084\u4f8b\uff09\u3001800 mg\uff083\u4f8b\uff09\u548c 1,000 mg\uff082\u4f8b\uff09\u3002<\/p>\n

\u7597\u6548\u6570\u636e\uff1a<\/p>\n

A \u7ec431\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u67093\u4f8b\uff089.7%\uff09\u8fbe\u5230\u4e86\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\uff0c7\u4f8b\uff0822.6%\uff09\u8fbe\u5230\u5f88\u597d\u7684\u90e8\u5206\u7f13\u89e3 (VGPR)\uff0c9\u4f8b\uff0829.0%\uff09\u8fbe\u5230\u90e8\u5206\u7f13\u89e3 (PR)\u3002\u603b\u53cd\u5e94\u7387\uff08ORR\uff09\u4e3a61.3%\uff0819\u4f8b\uff09\uff0c10\u4f8b\uff0832.3%\uff09\u8fbe\u5230\u2265 VGPR\u3002B\u7ec44\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\uff0c\u67092\u4f8b\uff0850%\uff09\u8fbe\u5230CR\uff0c2\u4f8b\uff0850%\uff09\u8fbe\u5230\u2265 VGPR\u3002C\u7ec47\u4f8b\u63a5\u53d7\u8bc4\u4f30\u7684\u60a3\u8005\u4e2d\uff0c1\u4f8b\uff0814.3%\uff09\u8fbe\u5230CR\uff0c4\u4f8b\uff0857.1%\uff09\u8fbe\u5230 VGPR\uff0c1\u4f8b\uff0814.3%\uff09\u8fbe\u5230PR\uff0c5\u4f8b\uff0871.4%\uff09\u8fbe\u5230\u2265 VGPR\uff0cORR \u4e3a 85.7%\uff086\u4f8b\uff09\uff1b2\u4f8b\u83b7\u5f97\u5fc3\u810f\u53cd\u5e94\u3002<\/p>\n

\u5b89\u5168\u6027\u6570\u636e\uff1a\u572849\u4f8b\u88ab\u7eb3\u5165\u5b89\u5168\u6027\u8bc4\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670934\u4f8b\uff0869.4%\uff09\u62a5\u544a\u4e86\u4efb\u4f55\u7ea7\u522b\u7684APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\uff08TRAEs\uff1b\u53d1\u751f\u7387\u22655%\uff09\uff0c\u5305\u62ec\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u75c7\uff0820.4%\uff09\u3001\u8840\u5c0f\u677f\u51cf\u5c11\uff086.1%\uff09\u3001\u767d\u7ec6\u80de\u51cf\u5c11\uff0810.2%\uff09\u3001\u6076\u5fc3\uff0816.3%\uff09\u3001\u8179\u80c0(10.2%\uff09\u3001\u8179\u6cfb\uff0812.2%\uff09\u548c\u4fbf\u79d8\uff088.2%\uff09\u3002\u5171\u670911\u4f8b\u60a3\u8005\u51fa\u73b0\u4e86\u22653\u7ea7\u7684TRAEs\uff0c\u5305\u62ec\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0814.3%\uff09\u548c\u53d1\u70ed\u6027\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff082%\uff09\uff0c3\u4f8b\u60a3\u8005\u51fa\u73b0\u4e86\u4e0eAPG-2575\uff08Lisaftoclax\uff09\u76f8\u5173\u7684\u4e25\u91cdAEs\uff0c\u5206\u522b\u4e3a\u53d1\u70ed\u6027\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u3001\u6025\u6027\u80be\u635f\u4f24\u548c\u8179\u6cfb\u4f34\u7535\u89e3\u8d28\u5931\u8861\uff08\u54041\u4f8b\uff09\u3002\u5728B\u7ec4\u4e2d\uff0c1\u4f8b\u60a3\u8005\u51fa\u73b0\u4e86\u5242\u91cf\u9650\u5236\u6027\u6bd2\u6027\uff08QT\u95f4\u671f\u5ef6\u957f\uff09\u3002\u836f\u4ee3\u52a8\u529b\u5b66\u5206\u6790\u8868\u660e\uff0c\u57283\u4e2a\u6cbb\u7597\u7ec4\u4e2d\uff0c\u6240\u6709\u60a3\u8005\u5728\u63a5\u53d7\u6240\u6307\u5b9a\u5242\u91cf\u7684APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u5176\u5b83\u6cbb\u7597\u836f\u7269\u6cbb\u7597\u65f6\u5747\u672a\u53d1\u751f\u836f\u7269\u76f8\u4e92\u4f5c\u7528\uff08DDI\uff09\u3002<\/p>\n

\u7ed3\u8bba\uff1a\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u8054\u5408Pd\u6216DRd\u65b9\u6848\u53ef\u63d0\u9ad8R\/R MM\u6216AL\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u7684\u7f13\u89e3\u6df1\u5ea6\u3002\u8fd9\u4e9b\u8054\u5408\u7597\u6cd5\u663e\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u5c24\u5176\u662f\u8840\u6db2\u5b66\u4e0d\u826f\u53cd\u5e94\u65b9\u9762\uff0c\u4e14\u65e0\u836f\u7269\u76f8\u4e92\u4f5c\u7528\u3002<\/p>\n

\u58c1\u62a5\u5c55\u793a\uff1a<\/p>\n

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given With Accelerated Ramp-up and Then Combined With Acalabrutinib or Rituximab in Patients (pts) With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL), Including Those With Prior Exposure to Venetoclax
Lisaftoclax\uff08APG-2575\uff09\u5728\u5feb\u901f\u5242\u91cf\u9012\u589e\u7ed9\u836f\u540e\u4e0e\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u6cbb\u7597\u5728\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5305\u62ec\u65e2\u5f80\u63a5\u53d7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005\u00a0<\/p>\n

\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a<\/p>\n

\u6458\u8981\u7f16\u53f7\uff1a4614<\/p>\n

\u5206\u4f1a\u573a\uff1a642. \u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\u7814\u7a76\uff1a\u58c1\u62a5\u5c55\u793aIII<\/p>\n

\u62a5\u544a\u65f6\u95f4\uff1a<\/p>\n

2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u56fd\u897f\u90e8\u65f6\u95f4\uff09
2024\u5e7412\u670810\u65e5\uff0c\u661f\u671f\u4e8c\uff0c\u4e0a\u534810:00 \u2013 12:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<\/p>\n

\u7b2c\u4e00\u4f5c\u8005\uff1a\u00a0\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09Matthew S. Davids\u535a\u58eb<\/p>\n

\u6838\u5fc3\u8981\u70b9\uff1a<\/p>\n

\u7814\u7a76\u80cc\u666f\uff1a\u7ef4\u5948\u514b\u62c9\uff08ven\uff09\u5bf9Bcl-2\u7684\u6291\u5236\u662fCLL\u6cbb\u7597\u7684\u91cd\u5927\u8fdb\u5c55\uff0c\u4f46\u4e3a\u51cf\u8f7b\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81\u548c\u836f\u7269\u76f8\u4e92\u4f5c\u7528\uff08DDI\uff09\u98ce\u9669\u800c\u8fdb\u884c\u76845\u5468\u5242\u91cf\u9012\u589e\u7ed9\u836f\u7684\u6cbb\u7597\u65b9\u5f0f\u4e9f\u5f85\u4f18\u5316\u3002APG-2575\uff08Lisaftoclax\uff09\u662f\u4e00\u79cd\u5728\u7814\u7684\u53e3\u670dBcl-2\u6291\u5236\u5242\uff0c\u5176\u534a\u8870\u671f\u77ed\uff0c\u53ef\u4ee5\u505a\u5230\u6bcf\u65e5\u5242\u91cf\u9012\u589e\u7ed9\u836f\u3002<\/p>\n

\u7814\u7a76\u4ecb\u7ecd\uff1a\u672c\u6b21\u516c\u5e03\u4e86APG-2575\uff08Lisaftoclax\uff09\u5355\u836f\u6216\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u521d\u6cbb\u00a0(TN\uff09\u3001\u590d\u53d1\/\u96be\u6cbb\u6027\uff08R\/R\uff09\u6216\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\uff08ven-treated\uff09\u6cbb\u7597\u7684CLL\/SLL\u7684\u6700\u65b0\u4e34\u5e8a\u6570\u636e\u3002<\/p>\n

\u5165\u7ec4\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n

\u4ece2020\u5e743\u670820\u65e5\u81f32024\u5e746\u670827\u65e5\uff0c\u5171\u5165\u7ec4176\u4f8b\u60a3\u8005\uff1a\u5355\u836f\u7ec446\u4f8b\uff1b\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u7ec439\u4f8b\uff1b\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u7ec491\u4f8b\u3002\u5176\u4e2dR\/R\u536087.5%\uff08154\/176\uff09, TN\u536012.5%\uff0822\/176\uff09\uff1b\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u5e74\u9f8463\uff0834-80\uff09\u5c81\uff1b67%\u4e3a\u7537\u6027\uff1b25.6% \u4f34\u6709del\uff0817p\uff09\u548c\/\u6216TP53\u7a81\u53d8\uff1b70.6% \u4f34\u6709\u00a0IGHV\u672a\u7a81\u53d8\u3002APG-2575\uff08Lisaftoclax\uff09\u7684\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u6301\u7eed\u6cbb\u7597\u65f6\u95f4\u5206\u522b\u4e3a16.5\uff081-54\uff1b\u5355\u836f\u7ec4\uff09\u4e2a\u6708\uff0c24\uff083-39\uff1b\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u7ec4\uff09\u4e2a\u6708\u548c27\uff081-43\uff1b\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u7ec4\uff09\u4e2a\u6708\u3002\u5728R\/R\u60a3\u8005\u4e2d\uff0c\u5148\u524d\u7684\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u6cbb\u7597\u7ebf\u6570\u4e3a2\uff081-15\uff09\uff0c14\u4f8b\uff089%\uff09\u60a3\u8005\u66fe\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u3002\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u5e74\u9f84\u4e3a65\u5c81\uff0851-78\u5c81\uff09\uff0c79%\u4e3a\u7537\u6027\u3002\u5728\u53ef\u8bc4\u4f30\u7684\u60a3\u8005\u4e2d\uff0c50%\u7684\u60a3\u8005\u6709del\uff0817p\uff09\uff0c36%\u7684\u60a3\u8005\u6709TP53\u7a81\u53d8\uff0c64%\u7684\u60a3\u8005\u6709del\uff0811q\uff09\uff0c38%\u7684\u60a3\u8005\u6709\u590d\u6742\u7684\u6838\u578b\uff08\u22653\u79cd\u5f02\u5e38\uff09\uff0c92%\u7684\u60a3\u8005\u6709\u672a\u7a81\u53d8\u7684IGHV\uff1b57%\u7684\u60a3\u8005\u65e2\u5f80\u672a\u63a5\u53d7\u8fc7BTK\u6291\u5236\u5242\u6cbb\u7597\uff1b\u65e2\u5f80\u6cbb\u7597\u7684\u4e2d\u4f4d\u6570\uff08\u8303\u56f4\uff09\u7ebf\u6570\u4e3a3\uff081-6\uff09\u3002\u60a3\u8005\u6bcf\u5929\u5355\u72ec\u53e3\u670dAPG-2575\uff08Lisaftoclax\uff09\u6216\u4e0e\u963f\u53ef\u66ff\u5c3c\uff08\u6301\u7eed\u6cbb\u7597\uff09\/\u5229\u59a5\u6614\u5355\u6297\uff086\u4e2a\u7597\u7a0b\uff09\u8054\u5408\u6cbb\u7597\uff0c\u6bcf28\u5929\u4e3a\u4e00\u7597\u7a0b\u3002APG-2575\uff08Lisaftoclax\uff09\u91c7\u75284-6\u5929\u6bcf\u5929\u68af\u5ea6\u9012\u589e\u7ed9\u836f\u7684\u65b9\u5f0f\uff0c\u4ece20mg\u5f00\u59cb\uff0c4-6\u5929\u540e\u53ef\u8fbe\u5230\u6700\u7ec8\u7684\u76ee\u6807\u5242\u91cf\uff08400\u3001600\u6216800 mg\uff09\u3002\u8054\u5408\u6cbb\u7597\u7ec4\u4e2d\u7684\u60a3\u8005\u4ece\u7b2c1\u5468\u671f\u7684\u7b2c8\u5929\uff08C1D8\uff09\u5f00\u59cb\u52a0\u5165\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\uff0c\u76f4\u81f3\u8fdb\u5c55\u6216\u7b2c24\u4e2a\u5468\u671f\u5b9e\u73b0\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u6216\u8005\u89c2\u5bdf\u5230\u4e0d\u53ef\u8010\u53d7\u7684\u6bd2\u6027\u3002<\/p>\n

\u7597\u6548\u6570\u636e\uff1a<\/p>\n

\u572887\u4f8b\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cORR\u4e3a96.6%\uff0c\u4e2d\u4f4d\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\uff08DOR; 95% CI, 23-NR\uff09\u548c\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS; 95% CI, 34-NR\uff09\u5747\u672a\u8fbe\u5230\u300212\u4e2a\u6708\u548c18\u4e2a\u6708\u7684PFS\u7387\u5206\u522b\u4e3a89%\u548c86%\u3002<\/p>\n

\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u6cbb\u7597\u7ec4\u4e2d\uff0c\u670914\u4f8b\u66fe\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597:<\/p>\n

\u5176\u4e2d9\u4f8b\u5728\u65e2\u5f80\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u4e2d\u8fdb\u5c55\uff0c3\u4f8b\u5728\u5b8c\u6210\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u540e\u590d\u53d1\uff0c2\u4f8b\u56e0\u7ef4\u5948\u514b\u62c9\u4e0d\u8010\u53d7\u800c\u505c\u836f\u3002\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u6cbb\u7597\u6301\u7eed\u65f6\u95f4\u4e3a16\uff083-25\uff09\u4e2a\u6708\u3002\u5b89\u5168\u6027\u4e0e\u5176\u4ed6\u7814\u7a76\u961f\u5217\u76f8\u4f3c\u3002\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cORR\u4e3a85.7%\uff0812\/14\uff09\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u4f46\u672a\u63a5\u53d7\u8fc7BTK\u6291\u5236\u5242\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cORR\u4e3a100%\uff088\/8\uff09\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u548cBTK\u6291\u5236\u5242\u6cbb\u7597\u7684\u60a3\u8005\u4e2d\uff0cORR\u4e3a66.7%\uff084\/6\uff09\uff1b\u4e2d\u4f4dDOR\u548cPFS\u672a\u8fbe\u5230\u300212\u4e2a\u6708\u548c18\u4e2a\u6708\u7684PFS\u7387\u5206\u522b\u4e3a84%\u548c73%\u3002<\/p>\n

\u5b89\u5168\u6027\u6570\u636e\uff1a<\/p>\n

\u5404\u961f\u5217TEAEs\u7684\u53d1\u751f\u7387\u548c\u4e25\u91cd\u7a0b\u5ea6\u76f8\u4f3c\u3002\u6240\u6709\u961f\u5217\u4e2d\u5e38\u89c1\u7684\uff08>10%\uff09\u4efb\u610f\u7ea7\u522bTEAEs \u4e3a\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0859\u4f8b[33.5%]\uff09\u3001\u8179\u6cfb\uff0838\u4f8b[21.6%]\uff09\u3001\u8d2b\u8840\uff0827\u4f8b[15.3%]\uff09\u548c\u8840\u5c0f\u677f\u51cf\u5c11\uff0826\u4f8b[14.8%]\uff09\u3002 \u22653\u7ea7TEAEs\u5728\u5355\u836f\u7ec4\u3001\u8054\u5408\u5229\u59a5\u6614\u5355\u6297\u7ec4\u548c\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u7ec4\u4e2d\u5206\u522b\u4e3a\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c1115\u4f8b\uff0832.6%\uff09\u300110\u4f8b\uff0825.6%\uff09\u548c22\u4f8b\uff0824%\uff09\uff0c\u8d2b\u884010\u4f8b\uff0821.7%\uff09\u30015\u4f8b\uff0812.8%\uff09\u548c12\u4f8b\uff0813.2%\uff09\u3002\u7efc\u5408E\u2011R\u5206\u6790\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u4f5c\u4e3a\u5355\u836f\u6cbb\u7597\u6216\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u65f6\u6709\u76f8\u4f3c\u7684\u5168\u8eab\u66b4\u9732\uff1bAPG-2575\uff08Lisaftoclax\uff09\u4e0e\u963f\u53ef\u66ff\u5c3c\u6216\u5229\u59a5\u6614\u5355\u6297\u8054\u5408\u4f7f\u7528\u65f6\u65e0DDI\u3002\u6ca1\u6709\u4e0eAPG-2575\uff08Lisaftoclax\uff09\u76f8\u5173\u7684TRAEs\u5bfc\u81f4\u505c\u836f\u300244\u4f8b\uff0895.7%\uff09\u63a5\u53d7\u5355\u836f\u6cbb\u7597\u7684\u60a3\u8005\u505c\u6b62\u4e86\u6cbb\u7597\u3002\u4e3b\u8981\u505c\u836f\u539f\u56e0\u662f\u75be\u75c5\u8fdb\u5c55\uff0841 \u4f8b[23.3%]\uff09\u548c AE\uff08 13 \u4f8b[7.4%] \uff09\uff1b9\u4f8b\uff085.1%\uff09\u60a3\u8005\u64a4\u56de\u77e5\u60c5\u540c\u610f\uff1b7\u4f8b\uff084%\uff09\u5728\u7b2c24\u4e2a\u5468\u671f\u53ca\u4ee5\u540e\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\u6216MRD\u9634\u6027\uff1b\u6b7b\u4ea15\u4f8b\uff082.8%\uff09\uff1b18\u4f8b\uff0810.2%\uff09\u56e0\u5176\u4ed6\u539f\u56e0\u505c\u836f\u30025\u4f8b\uff082.8%\uff09\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7597\u7684\u60a3\u8005\u89c2\u5bdf\u5230\u4e34\u5e8a\uff08n=2\uff09\u548c\u5b9e\u9a8c\u5ba4\uff08n=3\uff09TLS\uff08\u6839\u636eHoward\/Cairo-Bishop\u6807\u51c6\uff09\uff0c\u8fd9\u4e9b\u60a3\u8005\u8fc5\u901f\u6062\u590d\u5e76\u7ee7\u7eed\u5b89\u5168\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u6cbb\u7597\u3002<\/p>\n

\u7ed3\u8bba\uff1a\u6b64\u6b21\u7814\u7a76\u6570\u636e\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u963f\u53ef\u66ff\u5c3c\u5bf9\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005\u6709\u6548\uff0c\u5305\u62ec\u5728\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u4e2d\u8fdb\u5c55\u7684\u60a3\u8005\u3002\u8fd9\u9879\u968f\u8bbf\u65f6\u95f4\u8f83\u957f\u7684\u66f4\u65b0\u5206\u6790\u663e\u793a\uff0c\u5728\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u5355\u836f\u6cbb\u7597\/\u8054\u5408\u6cbb\u7597\u7684\u521d\u6cbb\u6216R\/R CLL\/SLL\u60a3\u8005\u4e2d\u672a\u89c2\u5bdf\u5230DDI\u6216\u65b0\u7684\u5b89\u5168\u6027\u95ee\u9898\u3002\u6211\u4eec\u4f1a\u7ee7\u7eed\u79ef\u7d2f\u65e2\u5f80\u63a5\u53d7\u8fc7\u7ef4\u5948\u514b\u62c9\u6cbb\u7597\u7684\u60a3\u8005\u6570\u636e\u6765\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u8fd9\u4e00\u9f13\u821e\u4eba\u5fc3\u7684\u7ed3\u679c\u3002APG-2575\uff08Lisaftoclax\uff09\u7684\u5168\u7403\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u76ee\u524d\u6b63\u5728\u5165\u7ec4\u4e2d\u3002<\/p>\n

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)\u00a0
\u65b0\u578bBcl-2\u6291\u5236\u5242Lisaftoclax\uff08APG-2575\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09<\/p>\n

\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u62a5\u5c55\u793a<\/p>\n

\u6458\u8981\u7f16\u53f7\uff1a3202<\/p>\n

\u5206\u4f1a\u573a\uff1a637. \u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff1a\u4e34\u5e8a\u53ca\u6d41\u884c\u75c5\u5b66\u7814\u7a76\uff1a\u58c1\u62a5\u5c55\u793aII<\/p>\n

\u62a5\u544a\u65f6\u95f4\uff1a<\/p>\n

2024\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u56fd\u897f\u90e8\u65f6\u95f4\uff09\/
2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u534810:00 \u2013 12:00\uff08\u5317\u4eac\u65f6\u95f4\uff09<\/p>\n

\u7b2c\u4e00\u4f5c\u8005\uff1a\u738b\u534e\u950b\u6559\u6388\uff0c\u6d59\u6c5f\u5927\u5b66\u533b\u5b66\u9662\u9644\u5c5e\u7b2c\u4e00\u533b\u9662<\/p>\n

\u6838\u5fc3\u8981\u70b9\uff1a<\/p>\n

\u7814\u7a76\u80cc\u666f\uff1a\u53bb\u7532\u57fa\u5316\u836f\u7269\uff08HMA\uff09\u4ecd\u7136\u662f\u9ad8\u5371MDS\u7684\u6807\u51c6\u6cbb\u7597\uff0c\u4f46\u4e34\u5e8a\u7597\u6548\u6b20\u4f73\u3002\u800cHMA\u6cbb\u7597\u5931\u8d25\/\u8010\u836f\u7684MDS\u60a3\u8005\uff0c\u9884\u540e\u5f88\u5dee\uff0c\u8fd9\u4e9b\u9ad8\u5371MDS\u60a3\u8005\u4e9f\u9700\u65b0\u7684\u6cbb\u7597\u65b9\u6848\u3002<\/p>\n

\u7814\u7a76\u4ecb\u7ecd\uff1a\u4e34\u5e8a\u524d\u6570\u636e\u663e\u793a\uff0c\u65b0\u578b\u7684Bcl-2\u6291\u5236\u5242APG-2575\uff08Lisaftoclax\uff09\u4e0eHMA\u8054\u5408\u53ef\u534f\u540c\u8bf1\u5bfcAML\u548cMDS\u80bf\u7624\u7ec6\u80de\u7684\u51cb\u4ea1\u3002\u6b64\u6b21\u4f1a\u8bae\u62a5\u544a\u7684\u662f\u4e00\u9879Ib\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u968f\u8bbf\u6570\u636e\uff0c\u91cd\u70b9\u8bc4\u4f30APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u6210\u4ebaMDS\u60a3\u8005\u7684\u7597\u6548\u3002<\/p>\n

\u5165\u7ec4\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n

\u8be5\u7814\u7a76\u7eb3\u5165\u9ad8\u5371MDS\u60a3\u8005\uff08IPSS-R\u8bc4\u5206> 3.5\uff1b\u9aa8\u9ad3\u539f\u59cb\u7ec6\u80de>5%\uff09\uff0c\u5305\u62ec\u521d\u6cbb\uff08TN\uff09\u548cR\/R MDS\u60a3\u8005\u3002APG-2575\uff08Lisaftoclax\uff09\u4f7f\u7528\u6307\u5b9a\u5242\u91cf\uff08400mg, 600mg\u6216800mg\uff09\uff0c\u6bcf\u5929\u4e00\u6b21\uff0c\u7b2c1\u5929\u81f3\u7b2c14\u5929\u4f7f\u7528\uff1b\u5728\u7b2c1\u5929\u81f3\u7b2c7\u5929\u8054\u5408\u4f7f\u7528\u963f\u624e\u80de\u82f7(75mg \/m2\/\u5929)\uff0c\u6bcf28\u5929\u4e3a\u4e00\u4e2a\u6cbb\u7597\u5468\u671f\u3002\u5728\u7b2c\u4e00\u4e2a\u6cbb\u7597\u5468\u671f\u4e2d\uff0cAPG-2575\uff08Lisaftoclax\uff09\u91c7\u7528\u6bcf\u65e5\u5242\u91cf\u9012\u589e\u65b9\u6848\u4ee5\u9884\u9632\u80bf\u7624\u6eb6\u89e3\u7efc\u5408\u5f81(TLS)\u3002\u8be5\u7814\u7a76\u7684\u4e3b\u8981\u76ee\u7684\u662f\u8bc4\u4f30\u6b64\u8054\u5408\u7597\u6cd5\u6cbb\u7597MDS\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff0c\u5e76\u786e\u5b9aAPG-2575\uff08Lisaftoclax\uff09\u7684\u63a8\u8350III\u671f\u5242\u91cf\u3002\u6839\u636e2006\u5e74\u56fd\u9645\u5de5\u4f5c\u7ec4\uff08IWG\uff09\u6807\u51c6\u8bc4\u4f30\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u548c\u9aa8\u9ad3\u5b8c\u5168\u7f13\u89e3\u7387\uff08mCR)\u3002\u622a\u81f32024\u5e747\u67081\u65e5\uff0c\u5171\u670949\u4f8b\u60a3\u8005\u5165\u7ec4\uff1a8\u4f8b\u4e3aR\/R MDS\uff08APG-2575 [Lisaftoclax] 600 mg [n = 5]\u548c800 mg [n = 3]\uff09\uff0c41\u4f8b\u4e3aTN MDS\uff08APG-2575 [Lisaftoclax] 400 mg [n = 16]\u3001600 mg [n = 23]\u548c800 mg [n = 2]\uff09\u3002\u4e2d\u4f4d\uff08\u8303\u56f4\uff09\u5e74\u9f84\u4e3a66\uff0822-83\uff09\u5c81\uff0c55.1%\u7684\u60a3\u8005\u4e3a\u7537\u6027\u3002IPSS-R\u98ce\u9669\u5206\u7ea7\u4e3a\u4e2d\u5371\uff0812\/49[24.5%]\uff09\u3001\u9ad8\u5371\uff0824\/49[49.0%]\uff09\u548c\u6781\u9ad8\u5371\uff0813\/49[26.5%]\uff09\u300239\u4f8b\u6709\u57fa\u56e0\u7a81\u53d8\u8c31\u6570\u636e\u7684\u60a3\u8005\u4e2d\uff0c9\u4f8b\uff0823.1%\uff09\u6709TP53\u7a81\u53d8\uff1b11\u4f8b\uff0828.2%\uff09\u6709TET2\u7a81\u53d8\uff1b10\u4f8b\uff0825.6%\uff09\u6709ASXL1\u7a81\u53d8\uff1b10\u4f8b\uff0825.6%\uff09\u6709RUNX1\u7a81\u53d8\u3002\u57fa\u7ebf\u65f6\uff0c70.8%\u7684\u60a3\u8005\u62a5\u544a\u4e86\u22653\u7ea7\u8d2b\u8840\uff1b54.2%\u62a5\u544a\u4e86\u22653\u7ea7\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff1b45.8%\u62a5\u544a\u4e86\u22653\u7ea7\u8840\u5c0f\u677f\u51cf\u5c11\u75c7\u3002<\/p>\n

\u7597\u6548\u6570\u636e\uff1a4\u4f8b\uff088.2%\uff09\u60a3\u8005\u66fe\u56e0\u4e0d\u826f\u4e8b\u4ef6\u5f15\u8d77APG-2575\uff08Lisaftoclax\uff09\u51cf\u91cf\u300260\u5929\u6b7b\u4ea1\u7387\u548cTLS\u53d1\u751f\u7387\u5747\u4e3a0\u3002\u57288\u4f8bR\/R MDS\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4d\u6cbb\u7597\u65f6\u95f4\uff08DOT\uff09\u4e3a3.2\uff081.2-9.4\uff09\u4e2a\u6708\u3002\u603b\u53cd\u5e94\u7387\uff08ORR = CR[12.5%] +mCR[62.5%]\uff09\u4e3a75.0%\uff0895% CI, 34.9-96.8\uff09\u3002\u572840\u4f8b\u53ef\u8bc4\u4f30\u7597\u6548\u7684TN MDS\u60a3\u8005\u4e2d\uff0c\u4e2d\u4f4dDOT\u4e3a4.5\uff080.5-12.1\uff09\u4e2a\u6708\uff1b\u6839\u636eIWG 2006\u6807\u51c6\uff0cORR\u7387\u4e3a77.5%\uff0895% CI, 61.5-89.2\uff09\uff0cCR\u7387\u4e3a25.0%\u3002\u6b64\u5916\uff0c23\u4f8b\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09600 mg\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u7684TN MDS\u60a3\u8005\u4e2d\uff0cORR\u548cCR\u7387\u5206\u522b\u4e3a73.9%\u548c30.4%\uff1b\u7531\u4e8e\u8fd9\u4e9b\u60a3\u8005\u7684\u4e2d\u4f4d\u6cbb\u7597\u65f6\u95f4\u76f8\u5bf9\u8f83\u957f\uff086.01\u4e2a\u6708\uff09\uff0c\u6211\u4eec\u6839\u636eIWG 2023\u6807\u51c6\u8fdb\u884c\u4e86\u8fdb\u4e00\u6b65\u5206\u6790\uff0c\u590d\u5408CR\u7387\uff08CR2023 = CR [52.2%] + CRL[17.4%]\uff09\u4e3a69.6%\uff0c\u4e2d\u4f4d\u8fbe\u5230CR\u65f6\u95f4\uff08\u8303\u56f4\uff09\u4e3a2.84\uff081.1-8.7\uff09\u4e2a\u6708\u3002\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\u548c\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\u5747\u672a\u8fbe\u5230\u3002<\/p>\n

\u5b89\u5168\u6027\u6570\u636e\uff1a<\/p>\n

\u6240\u6709\u63a5\u53d7APG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u6cbb\u7597\u7684\u60a3\u8005\u5747\u62a5\u544a\u4e86\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u4e0d\u826f\u4e8b\u4ef6(TEAEs)\uff0c\u5176\u4e2d93.8%\u4e3a\u22653\u7ea7\u4e0d\u826f\u4e8b\u4ef6\uff0c35.4%\u4e3a\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u3002\u5e38\u89c1\u7684\u22653\u7ea7\u975e\u8840\u6db2\u5b66TEAEs\uff08\u53d1\u751f\u7387\u226510%\uff09\u5305\u62ec\u80ba\u708e\uff0824.4%\uff09\u548c\u4f4e\u94be\u8840\u75c7\uff0810.2%\uff09\u3002\u5e38\u89c1\u7684\u22653\u7ea7\u8840\u6db2\u5b66TEAEs\u5305\u62ec\u767d\u7ec6\u80de\u8ba1\u6570\u51cf\u5c11\uff0875.5%\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0869.4%\uff09\u3001\u8840\u5c0f\u677f\u51cf\u5c11\uff0865.3%\uff09\u3001\u8d2b\u8840\uff0824.5%\uff09\u548c\u53d1\u70ed\u6027\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0818.4%\uff09\u300246.9%\u7684\u60a3\u8005\u62a5\u544a\u22653\u7ea7\u611f\u67d3\uff0c\u5176\u4e2d26.5%\u4e0e\u6cbb\u7597\u76f8\u5173\u300211\u4f8b\uff0822.4%\uff09\u60a3\u8005\u53d1\u751f\u4e86\u56e0\u4e0d\u826f\u4e8b\u4ef6\u5bfc\u81f4\u7684\u5468\u671f\u95f4\u6cbb\u7597\u5ef6\u8fdf\uff0c\u4e2d\u4f4d\u5ef6\u8fdf\u65f6\u95f4(\u8303\u56f4)\u4e3a12\uff081-63\uff09\u5929\u3002\u5171\u670995.9%\u7684\u60a3\u8005\u62a5\u544a\u4e86\u4e0e\u6cbb\u7597\u76f8\u5173\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d87.8%\u4e3a\u22653\u7ea7AEs\uff0c28.6%\u4e3a\u4e25\u91cdAEs\u3002\u5e38\u89c1\u7684\u22653\u7ea7\u8840\u6db2\u5b66TRAEs\u5305\u62ec\u767d\u7ec6\u80de\u8ba1\u6570\u51cf\u5c11\uff0871.4%\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0865.3%\uff09\u3001\u8840\u5c0f\u677f\u51cf\u5c11\uff0865.3%\uff09\u3001\u8d2b\u8840\uff0820.4%\uff09\u548c\u53d1\u70ed\u6027\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0812.2%\uff09\u3002<\/p>\n

\u7ed3\u8bba\uff1a\u4ee5\u4e0a\u4e34\u5e8a\u6570\u636e\u8868\u660e\uff0cAPG-2575\uff08Lisaftoclax\uff09\u8054\u5408\u963f\u624e\u80de\u82f7\u5728\u9ad8\u5371TN\u6216R\/R MDS\u60a3\u8005\u6cbb\u7597\u4e2d\u5177\u6709\u91cd\u8981\u4f5c\u7528\u3002\u8be5\u8054\u5408\u6cbb\u7597\u5448\u73b0\u826f\u597d\u7684\u6709\u6548\u6027\u548c\u8010\u53d7\u6027\uff0c60\u5929\u6b7b\u4ea1\u7387\u4e3a0\uff0c\u9700\u8981APG-2575\uff08Lisaftoclax\uff09\u51cf\u91cf\u7684\u60a3\u8005\u5c11\uff0c\u611f\u67d3\u7387\u4f4e\uff0c\u652f\u6301\u8be5\u8054\u5408\u6cbb\u7597\u5728\u9ad8\u98ce\u9669MDS\u60a3\u8005\u7684\u8fdb\u4e00\u6b65\u4e34\u5e8a\u5f00\u53d1\u3002<\/p>\n

\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/p>\n

\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7efc\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u7814\u53d1\u521b\u65b0\u836f\uff0c\u4ee5\u89e3\u51b3\u80bf\u7624\u7b49\u9886\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u5df2\u5efa\u7acb\u4e30\u5bcc\u7684\u521b\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216\u00a0MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u5df2\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5540\u591a\u9879\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5176\u4e2d\u5305\u62ec13\u9879\u6ce8\u518c\u4e34\u5e8a\u7814\u7a76\uff08\u5df2\u5b8c\u6210\/\u8fdb\u884c\u4e2d\/\u62df\u542f\u52a8\uff09\u3002<\/p>\n

\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u8010\u7acb\u514b\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u5df2\u88ab\u6210\u529f\u7eb3\u5165\u300a\u56fd\u5bb6\u57fa\u672c\u533b\u7597\u4fdd\u9669\u3001\u5de5\u4f24\u4fdd\u9669\u548c\u751f\u80b2\u4fdd\u9669\u836f\u54c1\u76ee\u5f55\u300b\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002<\/p>\n

\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9716\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0e\u6b66\u7530\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u3001\u4fe1\u8fbe\u7b49\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u4ee5\u53caMD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b66\u7b49\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002<\/p>\n

\u4e9a\u76db\u533b\u836f\u5df2\u6784\u5efa\u5728\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u9886\u57df\u7ecf\u9a8c\u4e30\u5bcc\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u4e0e\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c”\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42”\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

\u524d\u77bb\u6027\u58f0\u660e<\/p>\n

\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n

SOURCE \u4e9a\u76db\u533b\u836f<\/p>","protected":false},"excerpt":{"rendered":"

\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ —\u00a0\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u70b9\u54c1\u79cdAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u9009\u7b2c66\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u662f\u8be5\u54c1\u79cd\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u7b2c3\u5e74\u5165\u9009ASH\u5e74\u4f1a\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u4e2a\u54c1\u79cd\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9879\u4e34\u5e8a\u548c\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5e76\u83b7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u3002 APG-2575\uff08Lisaftoclax\uff09\u662f\u4e9a\u76db\u533b\u836f\u81ea\u4e3b\u7814\u53d1\u7684\u3001\u5177\u5168\u7403best-in-class\u6f5c\u529b\u7684\u65b0\u578b\u53e3\u670dBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\uff0c\u5728\u591a\u79cd\u8840\u6db2\u80bf\u7624\u548c\u5b9e\u4f53\u7624\u6cbb\u7597\u9886\u57df\u5177\u5907\u5e7f\u9614\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u4e9a\u76db\u533b\u836f\u5c06\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u4e0a\uff0c\u53e3\u5934\u62a5\u544a\u8be5\u54c1\u79cd\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\uff08R\/R\uff09\u591a\u53d1\u6027\u9aa8\u9ad3\u7624(MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6b64\u5916\uff0c\u5176\u8054\u5408\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6700\u65b0\u6570\u636e\u4e5f\u5c06\u4ee5\u58c1\u62a5\u5c55\u793a\u5f62\u5f0f\u516c\u5e03\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c66\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e\u5f53\u5730\u65f6\u95f42024\u5e7412\u67087\u65e5\u81f310\u65e5\u95f4\u5728\u7f8e\u56fd\u5723\u5730\u4e9a\u54e5\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”APG-2575\uff08Lisaftoclax\uff09\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\uff0c\u76ee\u524d\u6b63\u5728\u5f00\u5c55\u56db\u9879\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u3002\u8be5\u54c1\u79cd\u7684\u591a\u4e2a\u4e34\u5e8a\u8fdb\u5c55\u518d\u6b21\u5165\u9009ASH\u5e74\u4f1a\u62a5\u544a\uff0c\u8fdb\u4e00\u6b65\u4f53\u73b0APG-2575\uff08Lisaftoclax\uff09\u8fd9\u4e00\u5168\u7403Best-in-class\u6f5c\u529b\u54c1\u79cd\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u5f3a\u52b2\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u4e2a\u91cd\u70b9\u54c1\u79cd\u6709\u591a\u9879\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5145\u5206\u663e\u73b0\u4e86\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u548c\u5f00\u53d1\u5b9e\u529b\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u7684\u8be6\u5b9e\u6570\u636e\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” ASH 2024\u4e9a\u76db\u533b\u836f\u4ea7\u54c1\u76f8\u5173\u7814\u7a76\u4e00\u89c8\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u79cd \u6458\u8981\u6807\u9898 \u7f16\u53f7 \u53e3\u5934\u62a5\u544a \u5965\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Olverembatinib as Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597 480 APG-2575 \uff08Lisaftoclax\uff09 Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R\/R MM) or […]<\/p>\n","protected":false},"author":0,"featured_media":3566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-3565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\n\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u30102024-ash\u3011-\u4e9a\u76db\u533b\u836fbcl-2\u6291\u5236\u5242apg-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ —\u00a0\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u70b9\u54c1\u79cdAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u9009\u7b2c66\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u662f\u8be5\u54c1\u79cd\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u7b2c3\u5e74\u5165\u9009ASH\u5e74\u4f1a\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u4e2a\u54c1\u79cd\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9879\u4e34\u5e8a\u548c\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5e76\u83b7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u3002 APG-2575\uff08Lisaftoclax\uff09\u662f\u4e9a\u76db\u533b\u836f\u81ea\u4e3b\u7814\u53d1\u7684\u3001\u5177\u5168\u7403best-in-class\u6f5c\u529b\u7684\u65b0\u578b\u53e3\u670dBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\uff0c\u5728\u591a\u79cd\u8840\u6db2\u80bf\u7624\u548c\u5b9e\u4f53\u7624\u6cbb\u7597\u9886\u57df\u5177\u5907\u5e7f\u9614\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u4e9a\u76db\u533b\u836f\u5c06\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u4e0a\uff0c\u53e3\u5934\u62a5\u544a\u8be5\u54c1\u79cd\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\uff08R\/R\uff09\u591a\u53d1\u6027\u9aa8\u9ad3\u7624(MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6b64\u5916\uff0c\u5176\u8054\u5408\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6700\u65b0\u6570\u636e\u4e5f\u5c06\u4ee5\u58c1\u62a5\u5c55\u793a\u5f62\u5f0f\u516c\u5e03\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c66\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e\u5f53\u5730\u65f6\u95f42024\u5e7412\u67087\u65e5\u81f310\u65e5\u95f4\u5728\u7f8e\u56fd\u5723\u5730\u4e9a\u54e5\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”APG-2575\uff08Lisaftoclax\uff09\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\uff0c\u76ee\u524d\u6b63\u5728\u5f00\u5c55\u56db\u9879\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u3002\u8be5\u54c1\u79cd\u7684\u591a\u4e2a\u4e34\u5e8a\u8fdb\u5c55\u518d\u6b21\u5165\u9009ASH\u5e74\u4f1a\u62a5\u544a\uff0c\u8fdb\u4e00\u6b65\u4f53\u73b0APG-2575\uff08Lisaftoclax\uff09\u8fd9\u4e00\u5168\u7403Best-in-class\u6f5c\u529b\u54c1\u79cd\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u5f3a\u52b2\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u4e2a\u91cd\u70b9\u54c1\u79cd\u6709\u591a\u9879\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5145\u5206\u663e\u73b0\u4e86\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u548c\u5f00\u53d1\u5b9e\u529b\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u7684\u8be6\u5b9e\u6570\u636e\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” ASH 2024\u4e9a\u76db\u533b\u836f\u4ea7\u54c1\u76f8\u5173\u7814\u7a76\u4e00\u89c8\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u79cd \u6458\u8981\u6807\u9898 \u7f16\u53f7 \u53e3\u5934\u62a5\u544a \u5965\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Olverembatinib as Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597 480 APG-2575 \uff08Lisaftoclax\uff09 Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R\/R MM) or […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u30102024-ash\u3011-\u4e9a\u76db\u533b\u836fbcl-2\u6291\u5236\u5242apg-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-06T07:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"144\" \/>\n\t<meta property=\"og:image:height\" content=\"28\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/\",\"name\":\"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg\",\"datePublished\":\"2024-11-06T07:48:00+00:00\",\"dateModified\":\"2024-11-06T07:48:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg\",\"width\":144,\"height\":28},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u30102024-ash\u3011-\u4e9a\u76db\u533b\u836fbcl-2\u6291\u5236\u5242apg-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\/","og_locale":"en_US","og_type":"article","og_title":"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN","og_description":"\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02\u548c\u4e2d\u56fd\u82cf\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ —\u00a0\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u7b49\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\u2014\u2014\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u91cd\u70b9\u54c1\u79cdAPG-2575\uff08Lisaftoclax\uff09\u5171\u67093\u9879\u4e34\u5e8a\u8fdb\u5c55\u83b7\u9009\u7b2c66\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u4f1a\uff0c\u5176\u4e2d\u4e00\u9879\u83b7\u53e3\u5934\u62a5\u544a\u3002\u8fd9\u662f\u8be5\u54c1\u79cd\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u7b2c3\u5e74\u5165\u9009ASH\u5e74\u4f1a\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f8\u56db\u4e2a\u54c1\u79cd\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9879\u4e34\u5e8a\u548c\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5e76\u83b7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u3002 APG-2575\uff08Lisaftoclax\uff09\u662f\u4e9a\u76db\u533b\u836f\u81ea\u4e3b\u7814\u53d1\u7684\u3001\u5177\u5168\u7403best-in-class\u6f5c\u529b\u7684\u65b0\u578b\u53e3\u670dBcl-2\u9009\u62e9\u6027\u6291\u5236\u5242\uff0c\u5728\u591a\u79cd\u8840\u6db2\u80bf\u7624\u548c\u5b9e\u4f53\u7624\u6cbb\u7597\u9886\u57df\u5177\u5907\u5e7f\u9614\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u4e9a\u76db\u533b\u836f\u5c06\u5728\u6b64\u6b21ASH\u5e74\u4f1a\u4e0a\uff0c\u53e3\u5934\u62a5\u544a\u8be5\u54c1\u79cd\u6cbb\u7597\u590d\u53d1\/\u96be\u6cbb\uff08R\/R\uff09\u591a\u53d1\u6027\u9aa8\u9ad3\u7624(MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f7b\u94fe\uff08AL\uff09\u6dc0\u7c89\u6837\u53d8\u6027\u60a3\u8005\u7684I\/II\u671f\u4e34\u5e8a\u7814\u7a76\u6700\u65b0\u8fdb\u5c55\u3002\u6b64\u5916\uff0c\u5176\u8054\u5408\u6cbb\u7597\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3001\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684\u6700\u65b0\u6570\u636e\u4e5f\u5c06\u4ee5\u58c1\u62a5\u5c55\u793a\u5f62\u5f0f\u516c\u5e03\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u4f1a\u662f\u5168\u7403\u8840\u6db2\u5b66\u9886\u57df\u89c4\u6a21\u6700\u5927\u7684\u56fd\u9645\u5b66\u672f\u76db\u4f1a\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u76d6\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7597\u7814\u7a76\u3002\u7b2c66\u5c4aASH\u5e74\u4f1a\u5c06\u4e8e\u5f53\u5730\u65f6\u95f42024\u5e7412\u67087\u65e5\u81f310\u65e5\u95f4\u5728\u7f8e\u56fd\u5723\u5730\u4e9a\u54e5\u4ee5\u7ebf\u4e0b\u7ed3\u5408\u7ebf\u4e0a\u7684\u5f62\u5f0f\u4e3e\u884c\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a”APG-2575\uff08Lisaftoclax\uff09\u662f\u5168\u7403\u7b2c\u4e8c\u4e2a\u3001\u56fd\u5185\u9996\u4e2a\u770b\u5230\u660e\u786e\u7597\u6548\u3001\u5e76\u8fdb\u5165\u5173\u952e\u6ce8\u518c\u4e34\u5e8a\u9636\u6bb5\u7684Bcl-2\u6291\u5236\u5242\uff0c\u76ee\u524d\u6b63\u5728\u5f00\u5c55\u56db\u9879\u6ce8\u518cIII\u671f\u4e34\u5e8a\u7814\u7a76\u3002\u8be5\u54c1\u79cd\u7684\u591a\u4e2a\u4e34\u5e8a\u8fdb\u5c55\u518d\u6b21\u5165\u9009ASH\u5e74\u4f1a\u62a5\u544a\uff0c\u8fdb\u4e00\u6b65\u4f53\u73b0APG-2575\uff08Lisaftoclax\uff09\u8fd9\u4e00\u5168\u7403Best-in-class\u6f5c\u529b\u54c1\u79cd\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u5f3a\u52b2\u7684\u6cbb\u7597\u6f5c\u529b\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u4e2a\u91cd\u70b9\u54c1\u79cd\u6709\u591a\u9879\u8fdb\u5c55\u5165\u9009ASH\u5e74\u4f1a\u5c55\u793a\u53ca\u62a5\u544a\uff0c\u5145\u5206\u663e\u73b0\u4e86\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u548c\u5f00\u53d1\u5b9e\u529b\u3002\u6211\u4eec\u671f\u5f85\u5728\u540e\u7eed\u4f1a\u8bae\u671f\u95f4\u4e0e\u5927\u5bb6\u5206\u4eab\u76f8\u5173\u7814\u7a76\u7684\u8be6\u5b9e\u6570\u636e\u3002\u672a\u6765\uff0c\u4e9a\u76db\u533b\u836f\u5c06\u8fdb\u4e00\u6b65\u52a0\u901f\u63a8\u8fdb\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u4e3a\u60a3\u8005\u5e26\u6765\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u3002” ASH 2024\u4e9a\u76db\u533b\u836f\u4ea7\u54c1\u76f8\u5173\u7814\u7a76\u4e00\u89c8\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u79cd \u6458\u8981\u6807\u9898 \u7f16\u53f7 \u53e3\u5934\u62a5\u544a \u5965\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Olverembatinib as Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) \u5965\u96f7\u5df4\u66ff\u5c3c\u7528\u4e8e\u6162\u6027\u671f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597 480 APG-2575 \uff08Lisaftoclax\uff09 Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R\/R MM) or […]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u30102024-ash\u3011-\u4e9a\u76db\u533b\u836fbcl-2\u6291\u5236\u5242apg-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\/","og_site_name":"Money Compass CN","article_published_time":"2024-11-06T07:48:00+00:00","og_image":[{"width":144,"height":28,"url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/","url":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/","name":"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01 - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg","datePublished":"2024-11-06T07:48:00+00:00","dateModified":"2024-11-06T07:48:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-EXTt44.jpeg","width":144,"height":28},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e3%80%902024-ash%e3%80%91-%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%afbcl-2%e6%8a%91%e5%88%b6%e5%89%82apg-2575%e4%b8%89%e9%a1%b9%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e5%85%a5%e9%80%89%ef%bc%8c%e5%90%ab1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u30102024 ASH\u3011 \u4e9a\u76db\u533b\u836fBcl-2\u6291\u5236\u5242APG-2575\u4e09\u9879\u4e34\u5e8a\u7814\u7a76\u5165\u9009\uff0c\u542b1\u9879\u53e3\u5934\u62a5\u544a\uff01"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/3565"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=3565"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/3565\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/3566"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=3565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=3565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=3565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}